# Phase II/III Trial of CPT-11/5-FU/l-LV Versus CPT-11/TS-1 as Second Line Chemotherapy of Unresectable Colorectal Cancer

> **NCT00284258** · PHASE2,PHASE3 · COMPLETED · sponsor: **Taiho Pharmaceutical Co., Ltd.** · enrollment: 426 (actual)

## Conditions studied

- Colorectal Cancer

## Interventions

- **DRUG:** CPT-11 and TS-1
- **DRUG:** CPT-11, 5-FU and l-LV

## Key facts

- **NCT ID:** NCT00284258
- **Lead sponsor:** Taiho Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-01
- **Primary completion:** 2010-07
- **Final completion:** 2010-08
- **Target enrollment:** 426 (ACTUAL)
- **Last updated:** 2012-11-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00284258

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00284258, "Phase II/III Trial of CPT-11/5-FU/l-LV Versus CPT-11/TS-1 as Second Line Chemotherapy of Unresectable Colorectal Cancer". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT00284258. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*